Plasma Kinetic Resection of Prostate Combined Terazosin for Treatment of BPH Patient with Coexisting Hypertension

Objective: To evaluate the efficacy and safety of terazosin and plasma kinetic resection of the prostate (PKRP) in the treatment of benign prostatic hyperplasia (BPH) patients with coexisting hypertension. Methods: A total of 205 men who suffered from BPH with concomitant hypertension were enrolled in this study. They all received PKRP surgery and terazosin medication from one week before to 3 months after the operation. The procedures of efficacy and safety were evaluated by analysis of the changes in blood pressures, IPSS, Qmax and the drug related adverse events 4 weeks and 3 months after the operation. Results: The systolic blood pressure decreased from 161 ± 12.33 mmHg at baseline to 148 ± 7.27 mmHg four weeks (P < 0.05) and to 132 ± 6.13 mmHg three months after the operation (P < 0.01), the diastolic blood pressure decreased from 102 ± 4.99 mmHg to 95 ± 4.61 mmHg four weeks (P < 0.05) and to 81 ± 4.26 mmHg three months after the operation (P < 0.01). The IPSS reduced from 21 ± 4.82 to 15 ± 3.66 four weeks (P < 0.05) and to 12 ± 3.11 three months after the operation (P < 0.01). The Qmax were improved from 7 ± 4.41 to 12 ± 1.34 four weeks and to 15 ± 2.92 three months after the operation (P < 0.05). There were no notable adverse events. Conclusions: PKRP combined with terazosin in treating BPH with concomitant hypertension patient is a safe and effective procedure with a good patient compliance.